Protalix Biotherapeutics Inc. buy stratec
Start price
03.02.18
/
50%
€5.13
Target price
04.11.21
€4.00
Performance (%)
-81.68%
End price
05.11.21
€0.94
Summary
This prediction ended on 05.11.21 with a price of €0.94. The BUY prediction by stratec for Protalix Biotherapeutics Inc. performed very badly with a performance of -81.68%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | 8.967% | 8.967% | 64.103% | -5.882% |
| iShares Core DAX® | 0,56 % | 0,44 % | 5,87 % | 54,93 % |
| iShares Nasdaq 100 | -0,16 % | 1,62 % | 37,06 % | 90,56 % |
| iShares Nikkei 225® | 1,10 % | 9,61 % | 65,64 % | 80,26 % |
| iShares S&P 500 | 0,01 % | 0,69 % | 25,68 % | 67,61 % |
Comments by stratec for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix is a Buy for investors who are patient and brave...
Protalix has the first FDA-approved plant cell expressed protein, Elelyso for Gaucher disease, and has three other drug candidates in its pipeline.
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). Phase 3 interim data for its Fabry disease franchise will be reported in 2018. PRX-102 has less antibody formation (and antibodies only stay in the body briefly).
The orphan disease market is lucrative with PRX-102 to potentially become the new standard of care.
stratec stimmt am 03.02.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 5.22€ zu.
Kursziel geändert auf 2,2
Kursziel geändert auf 3,0
Kursziel geändert auf 4,0
In the thread Trading Protalix Biotherapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten